Valuation Neuland Laboratories Limited

Stocks

Market Closed - Bombay S.E. 13:02:33 23/10/2026 +03			5-day change	1st Jan Change
18,924.25 ^INR	-0.01%		-3.94%	+24.58%

09-15	Neuland Laboratories Limited Accelerates Peptide Manufacturing Expansion with Operational Module and Additional Capacity Expansion Underway	CI
09-08	Indian shares on track for muted open as oil climbs on rising Mideast risks	RE

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	13,171	23,087	80,588	154,946	154,121	242,796	-	-
Change	-	75.28%	249.07%	92.27%	-0.53%	57.54%	-	-
Enterprise Value (EV) ¹	13,171	23,087	80,374	153,929	153,584	245,486	244,374	241,118
Change	-	75.28%	248.14%	91.52%	-0.22%	59.84%	-0.45%	-1.33%
P/E	20.6x	14.1x	26.9x	-	42.3x	50.8x	38.9x	28.6x
PBR	1.58x	-	6.32x	10.2x	8.27x	10.5x	8.41x	6.73x
PEG	-	0x	0.3x	-	-	1.6x	1.3x	0.8x
Capitalization / Revenue	1.38x	1.94x	5.17x	10.5x	7.62x	10x	8.36x	6.98x
EV / Revenue	1.38x	1.94x	5.16x	10.4x	7.59x	10.2x	8.41x	6.93x
EV / EBITDA	9.24x	8.49x	17.4x	47.6x	26.7x	34x	26.2x	20x
EV / EBIT	14.1x	-	19.9x	59.7x	31.8x	39.5x	29.5x	22.8x
EV / FCF	-35.3x	13.5x	68.4x	139x	-304x	55x	60.4x	40.1x
FCF Yield	-2.83%	7.41%	1.46%	0.72%	-0.33%	1.82%	1.66%	2.49%
Dividend per Share ²	-	10	14	12	34	22.69	30.13	57.02
Rate of return	-	0.56%	0.22%	0.1%	0.28%	0.12%	0.16%	0.3%
EPS ²	49.74	127.4	233.9	-	283.7	372.7	486.5	661.4
Distribution rate	-	7.85%	5.99%	-	12%	6.09%	6.19%	8.62%
Net sales ¹	9,511	11,912	15,586	14,768	20,230	24,177	29,057	34,789
EBITDA ¹	1,426	2,718	4,626	3,233	5,745	7,227	9,330	12,070
EBIT ¹	935.8	-	4,029	2,577	4,828	6,207	8,281	10,592
Net income ¹	638.2	1,635	3,001	2,601	3,640	4,798	6,265	8,532
Net Debt ¹	-	-	-214.1	-1,017	-536.9	2,690	1,578	-1,678
Reference price ²	1,026.60	1,799.45	6,281.30	12,076.95	12,012.65	18,924.25	18,924.25	18,924.25
Nbr of stocks (in thousands)	12,830	12,830	12,830	12,830	12,830	12,830	-	-
Announcement Date	5/10/22 A	5/11/23 A	5/10/24 A	5/15/25 A	5/12/26 A	-	-	-

¹INR in Million²INR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
NEULAND LABORATORIES LIMITED	50.78x	10.15x	33.97x	0.12%	2.56B
ELI LILLY AND COMPANY	36.74x	13.1x	27.8x	0.54%	1,135B
JOHNSON & JOHNSON	38.61x	6.5x	18.29x	2.02%	636B
ABBVIE INC.	36.46x	8.38x	17.29x	2.41%	505B
ROCHE HOLDING AG	20.87x	5.11x	12.73x	2.56%	378B
MERCK & CO., INC.	105.89x	5.92x	25.41x	2.34%	358B
NOVARTIS AG	21.76x	5.67x	13.94x	2.81%	295B
ASTRAZENECA PLC	22.42x	4.53x	12.96x	1.95%	266B
AMGEN INC.	27.87x	7.16x	12.81x	2.3%	237B
GILEAD SCIENCES, INC.	-45.48x	6.98x	27.06x	2.11%	193B
Average	31.59x	7.35x	20.22x	1.92%	400.69B
Weighted average by Cap.	35.15x	8.30x	20.40x	1.8%